Scarica l'app Stockscreener
20.43
2.43%
-0.34
Precedente Chiudi:
$20.77
Aprire:
$20.88
Volume 24 ore:
21,159
Relative Volume:
0.09
Capitalizzazione di mercato:
$614.73M
Reddito:
$4.12M
Utile/perdita netta:
$-56.68M
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
$-51.44M
1 W Prestazione:
-20.50%
1M Prestazione:
-28.59%
6M Prestazione:
-17.52%
1 anno Prestazione:
+76.22%
Intervallo 1D:
$19.84
$20.88
Intervallo di 1 settimana:
$19.84
$25.93
Portata 52W:
$6.58
$33.77
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Nome
Dianthus Therapeutics Inc
Settore
Industria
Telefono
857-201-2700
Indirizzo
300 TECHNOLOGY SQUARE, CAMBRIDGE
Confronta DNTH con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| DNTH | 20.27 | 614.73M | 4.12M | -56.68M | -51.44M | 0.00 |
| VRTX | 446.78 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.30 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 586.52 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.35 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.55 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-07-26 | Iniziato | Robert W. Baird | Outperform |
| 2024-06-27 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-05-16 | Iniziato | H.C. Wainwright | Buy |
| 2024-02-15 | Iniziato | Stifel | Buy |
| 2023-12-26 | Iniziato | Jefferies | Buy |
| 2023-11-22 | Iniziato | Wedbush | Outperform |
| 2023-10-30 | Iniziato | Guggenheim | Buy |
| 2023-09-28 | Iniziato | Raymond James | Outperform |
| 2022-08-25 | Downgrade | Goldman | Buy → Neutral |
| 2022-01-06 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-08-20 | Ripresa | Goldman | Neutral |
| 2021-08-03 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-07-22 | Reiterato | B. Riley Securities | Buy |
| 2021-06-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-18 | Iniziato | B. Riley Securities | Buy |
| 2021-01-07 | Iniziato | Mizuho | Buy |
| 2020-06-08 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-03-25 | Downgrade | Goldman | Buy → Neutral |
| 2019-03-15 | Iniziato | Raymond James | Outperform |
Mostra tutto
Dianthus Therapeutics Inc Borsa (DNTH) Ultime notizie
Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Tops Revenue Estimates - MSN
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Sees Large Growth in Short Interest - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 8.1%Should You Sell? - MarketBeat
What is HC Wainwright's Estimate for DNTH FY2024 Earnings? - MarketBeat
Raymond James Forecasts Strong Price Appreciation for Dianthus Therapeutics (NASDAQ:DNTH) Stock - Defense World
Evaluating Dianthus Therapeutics: Insights From 5 Financial Analysts - Benzinga
Dianthus Therapeutics' (DNTH) Buy Rating Reiterated at HC Wainwright - MarketBeat
Oppenheimer Issues Positive Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price - MarketBeat
Dianthus Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Up After Analyst Upgrade - Defense World
A Glimpse Into The Expert Outlook On Dianthus Therapeutics Through 4 Analysts - Benzinga
Dianthus Therapeutics (NASDAQ:DNTH) Price Target Raised to $56.00 - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap UpHere's Why - MarketBeat
Dianthus Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Dianthus Therapeutics Reports Q3 Progress and Financials - TipRanks
Dianthus Therapeutics Reports $342.6M Cash Runway, Advances Phase 3 CIDP Trial Plans | DNTH Stock News - StockTitan
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Rating of “Buy” by Analysts - Defense World
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Rating of "Buy" by Analysts - MarketBeat
Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences - The Manila Times
Financial Analysis: Dianthus Therapeutics (NASDAQ:DNTH) and Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World
SG Americas Securities LLC Increases Stock Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 5%Should You Buy? - MarketBeat
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting - The Manila Times
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 4.4%Here's What Happened - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives $45.13 Consensus Target Price from Brokerages - MarketBeat
Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.7% Jump Turn into More Strength? - Yahoo Finance
Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 4.5% – Still a Buy? - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 4.5%Should You Buy? - MarketBeat
Dianthus: Modest Opportunity With 2 Caveats (NASDAQ:DNTH) - Seeking Alpha
Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 5.7%Here's Why - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Sees Unusually-High Trading Volume – Still a Buy? - Defense World
Marshall Wace LLP Sells 4,731 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dianthus started at outperform by Oppenheimer on DNTH103 opportunity - MSN
Dianthus started at outperform by Oppenheimer on DNTH103 opportunity (NASDAQ:DNTH) - Seeking Alpha
Oppenheimer Initiates Coverage on Dianthus Therapeutics (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Sold by Point72 Asset Management L.P. - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Down to $27.88 - Defense World
Renaissance Technologies LLC Lowers Stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
American Century Companies Inc. Increases Stock Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Fred Alger Management LLC Has $163,000 Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Rating Reiterated by HC Wainwright - MarketBeat
Expert Ratings For Dianthus Therapeutics - Benzinga
Point72 Asia Singapore Pte. Ltd. Acquires 29,159 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Point72 Asia Singapore Pte. Ltd. Has $1.02 Million Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Insider Selling: Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Sells 40,831 Shares of Stock - Defense World
Dirk Kersten Sells 79,411 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) Stock - Defense World
Logos Global Management LP Sells 1,465,000 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Dyne Therapeutics (NASDAQ:DYN) Shares Down 3% - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Holdings Boosted by Great Point Partners LLC - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) and Oramed Pharmaceuticals (NASDAQ:ORMP) Financial Review - Defense World
Dianthus Therapeutics Inc Azioni (DNTH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.42%
0.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):